High-dose therapy in patients with Hodgkin's disease:: the use of selected CD34+ cells is as safe as unmanipulated peripheral blood progenitor cells

被引:16
作者
Blystad, AK [1 ]
Holte, H
Kvaloy, S
Smeland, E
Delabie, J
Kvalheim, G
机构
[1] Norwegian Radium Hosp, Dept Oncol, N-0310 Oslo, Norway
[2] Norwegian Radium Hosp, Dept Immunol, N-0310 Oslo, Norway
[3] Norwegian Radium Hosp, Dept Pathol, N-0310 Oslo, Norway
关键词
Hodgkin's disease; autologous stem cell transplantation; CD34(+) cell enrichment;
D O I
10.1038/sj.bmt.1703244
中图分类号
Q6 [生物物理学];
学科分类号
071011 ;
摘要
Register data suggest that patients with Hodgkin's disease (HD) given high-dose therapy (HDT) with peripheral blood progenitor cells (PBPC) have a less favourable prognosis as compared to those given bone marrow as stem cell support. Since this can be due to infusion of tumour cells contaminating the PBPC grafts, we initiated a feasibility study in which PBPC grafts from HD patients were purged by CD34(+) cell enrichment. Controversy exists about whether the use of CD34(+) enriched stem cells leads to a delayed haematological and immune reconstitution. We compared these parameters, including risk of infections and clinical outcome after HDT, in patients with HD given either selected CD34+ cells or unmanipulated PBPC as stem cell support. From October 1994 to May 2000, 40 HD patients with primary refractory disease or relapse were treated with HDT and supported with either selected CD34(+) cells (n = 21) or unmanipulated PBPC (n = 19) as stem cell support. All patients had chemosensitive disease at the time of transplantation. A median of 5.8 (range 2.7-20.0) vs 4.5 (range 2.3-17.6) x 10(6) CD34(+) cells per kilo were reinfused in the CD34(+) group and PBPC group, respectively. No difference was observed between the two groups with regard to time to haematological engraftment, reconstitution of B cells, CD56(+) cells and T cells at 3 and 12 months and infectious episodes after HDT. Two (5%) treatment-related deaths, one in each group, were observed. The overall survival at 4 years was 86% for the CD34(+) group and 74% for the PBPC group with a median follow-up of 37 months (range 1-61) and 46 months (range 4-82), respectively (P = 0.9). The results of this study demonstrate that the use of CD34(+) cells is safe and has no adverse effects either with respect to haematological, immune reconstitution or to infections after HDT.
引用
收藏
页码:849 / 857
页数:9
相关论文
共 40 条
[1]   High-dose chemotherapy and stem cell transplantation for patients with stage IV breast cancer without clinically evident disease:: correlation of CD34+ selection to clinical outcome [J].
Ahmed, T ;
Kancherla, R ;
Qureshi, Z ;
Mittelman, A ;
Seiter, K ;
Mannancheril, A ;
Puccio, C ;
Chun, HG ;
Bar, M ;
Lipshutz, M ;
Ali, MF ;
Goldberg, R ;
Preti, R ;
Lake, D ;
Durrani, H ;
Farley, T .
BONE MARROW TRANSPLANTATION, 2000, 25 (10) :1041-1045
[2]   Combination chemotherapy with mitoguazon, ifosfamide, MTX, etoposide (MIME) and G-CSF can efficiently mobilize PBPC in patients with Hodgkin's and non-Hodgkin's lymphoma [J].
Aurlien, E ;
Holte, H ;
Pharo, A ;
Kvaloy, S ;
Jakobsen, E ;
Smeland, EB ;
Kvalheim, G .
BONE MARROW TRANSPLANTATION, 1998, 21 (09) :873-878
[3]  
BERENSON RJ, 1991, BLOOD, V77, P1717
[4]   CD34+ cell enrichment depletes atypical CD30+ cells from PBPC grafts in patients with HD [J].
Blystad, AK ;
Torlakovic, E ;
Holte, H ;
Kvaloy, S ;
Lenschow, E ;
Kvalheim, G .
CYTOTHERAPY, 2001, 3 (04) :295-305
[5]  
Blystad AK, 1999, BLOOD, V94, p142A
[6]   Lymphoid reconstitution after autologous PBSC transplantation with FACS-sorted CD34+ hematopoietic progenitors [J].
Bomberger, C ;
Singh-Jairam, M ;
Rodey, G ;
Guerriero, A ;
Yeager, AM ;
Fleming, WH ;
Holland, HK ;
Waller, EK .
BLOOD, 1998, 91 (07) :2588-2600
[7]   GENE-MARKING TO TRACE ORIGIN OF RELAPSE AFTER AUTOLOGOUS BONE-MARROW TRANSPLANTATION [J].
BRENNER, MK ;
RILL, DR ;
MOEN, RC ;
KRANCE, RA ;
MIRRO, J ;
ANDERSON, WF ;
IHLE, JN .
LANCET, 1993, 341 (8837) :85-86
[8]  
BRUGGER W, 1994, BLOOD, V83, P636
[9]   POSITIVELY SELECTED AUTOLOGOUS BLOOD CD34+ CELLS AND UNSEPARATED PERIPHERAL-BLOOD PROGENITOR CELLS MEDIATE IDENTICAL HEMATOPOIETIC ENGRAFTMENT AFTER HIGH-DOSE VP16, IFOSFAMIDE, CARBOPLATIN, AND EPIRUBICIN [J].
BRUGGER, W ;
HENSCHLER, R ;
HEIMFELD, S ;
BERENSON, RJ ;
MERTELSMANN, R ;
KANZ, L .
BLOOD, 1994, 84 (05) :1421-1426
[10]  
Diviné M, 1999, BRIT J HAEMATOL, V105, P349, DOI 10.1046/j.1365-2141.1999.01344.x